Butler University

Digital Commons @ Butler University
Scholarship and Professional Work – COPHS

College of Pharmacy & Health Sciences

2003

Pulmonary Embolism as an Adverse Drug Event of Intravenous
Immunoglobulin Therapy
Katasha S. Butler
Deborah S. Zeitlin
Butler University, dzeitlin@butler.edu

Follow this and additional works at: https://digitalcommons.butler.edu/cophs_papers
Part of the Pharmacy and Pharmaceutical Sciences Commons

Recommended Citation
Butler, Katasha S. and Zeitlin, Deborah S., "Pulmonary Embolism as an Adverse Drug Event of Intravenous
Immunoglobulin Therapy" (2003). Scholarship and Professional Work – COPHS. 182.
https://digitalcommons.butler.edu/cophs_papers/182

This Letter to the Editor is brought to you for free and open access by the College of Pharmacy & Health Sciences
at Digital Commons @ Butler University. It has been accepted for inclusion in Scholarship and Professional Work –
COPHS by an authorized administrator of Digital Commons @ Butler University. For more information, please
contact digitalscholarship@butler.edu.

Pulmonary Embolism Associated with Intravenous Immunoglobulin
Therapy

Katasha S Butler, PharmD
Butler University, 9033 Cinnebar Drive, Indianapolis, Indiana 46268-1239, FAX
317/925-0280
Deborah S Zeitlin, PharmD
Clinical Pharmacist, Anticoagulation Clinic, Community Health Network,
Indianapolis

TO THE EDITOR: Intravenous immunoglobulin (IVIG) therapy has gained popularity for the treatment of
neuromuscular diseases (i.e., myasthenia gravis, inflammatory myopathy, chronic inflammatory
demyelinating polyneuropathy), although adverse events are associated with high-dose IVIG infusions.1,2
Common adverse reactions to IVIG therapy are anxiety, headache, fever, chills, chest pain, dyspnea, nausea,
and abdominal pain.3 More serious adverse events include anaphylaxis, hemolytic anemia, hepatitis C, and
thrombosis.3 Studies have shown documented effects of IVIG on blood rheology. It increases plasma
viscosity in a dose-related response and may also activate platelets.2–4 High-dose IVIG therapy is
approximately 24–54 g/d.4

Case Report. A 55-year-old white man presented to the emergency department (ED) complaining
of chest pain and shortness of breath for 5 days in mid-2002. The patient's past medical history
included sleep apnea, hypertension, deep-vein thrombosis (DVT), peripheral neuropathy, and
immunosuppressive syndrome. He had no history of diabetes or heart or lung disease, and his
family history was noncontributory. Current medications included warfarin for treatment of DVT
caused by Port-A-Cath and IVIG for peripheral neuropathy. He also used
oxycodone/acetaminophen and amitriptyline as needed. The patient used continuous positive
airway pressure for sleep apnea. His last IVIG infusion had been administered 7 days prior to the
ED visit. Abnormal laboratory test findings in ED were international normalized ratio (INR) 1.73
(normal 2–3), partial thromboplastin time 45.7 seconds (21–35), pH 7.47 (7.36–7.44), and pO2 60
mmHg (90–100). A computed tomography scan of the chest discovered bilateral pulmonary
embolism in the right lower and left upper lobes. He was admitted to the hospital with severe
stenosis extending to the occlusion of the left subclavian vein, and his left inominate vein was
thrombosed by >5 cm.
The patient had a history of thrombosis, and now bilateral pulmonary emboli were noted without
obvious triggering factors. Upon further investigation, we found that the patient had been evaluated
at another institution for peripheral neuropathy of unknown origin in 2000. He suffered from
severe burning, tingling, numbness, and pain in his extremities that was incapacitating when he
was not receiving IVIG. He had developed his first DVT in late 2001. At that time, the patient
started IVIG infusions twice weekly. Due to cost issues, the infusions were decreased to once a
week at the beginning of 2002. After evaluating all potential causes for thrombosis, including the
subtherapeutic INR upon admission, IVIG was determined to be the most probable cause of
pulmonary embolism according to the Naranjo probability scale,5 and the patient was advised to
discontinue IVIG therapy. Inpatient treatment for pulmonary embolism included enoxaparin and
warfarin and, on discharge, the patient was prescribed subcutaneous enoxaparin 100 mg twice
daily for 7 days and warfarin 7.5 mg 1 day per week and 5 mg on all other days, adjusted to an
INR goal of 2.5–3.5.
Discussion. To date, there have been <15 cases reported concerning thrombotic events related to
IVIG therapy.2 Caution should be used when considering IVIG therapy in the geriatric population
and patients with known risk factors such as history of pulmonary embolism, DVT, stroke,
myocardial infarction, cardiac valve replacement, or low cardiac output.1,3
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